rethinkTHC Search
Menu
Study breakdown

CBD Showed Promising but Inconclusive Heart Recovery Benefits in Acute Myocarditis Trial

Randomized Controlled TrialModerate evidence
The takeaway

In a 109-patient RCT, CBD did not meet primary cardiac endpoints in acute myocarditis, but significantly reduced left ventricular mass and showed an anti-inflammatory trend.

Cardiologists; myocarditis researchers; CBD developers.

Significant LV mass reduction (-9.2g, p=0.012) but primary endpoints missed

What the researchers found

CBD (up to 10 mg/kg BID for 12 weeks) did not significantly improve ECV (p=0.054) or GLS (p=0.90). LV mass was significantly reduced (-9.2g, p=0.012). LAESV decreased (-8.1 ml, p=0.038). 100% completion rate.

Why it matters

First RCT of CBD in cardiac inflammation. While primary endpoints were missed, secondary findings suggest anti-inflammatory cardiac effects worth investigating.

The numbers in context

109 patients, 100% completion. ECV: -3.7 ml (p=0.054). LV mass: -9.2g (p=0.012). LAESV: -8.1 ml (p=0.038). GLS: -0.1 (p=0.90).

How the study worked

ARCHER Study: multicenter double-blind placebo-controlled phase 2 trial. 109 patients with CMR-confirmed acute myocarditis. 56 CBD, 53 placebo for 12 weeks.

What this study cannot tell us

Primary endpoints not met. Mild-moderate myocarditis with preserved LV function at baseline. Small sample. Phase 2.

How to read the evidence

Well-designed international RCT with 100% completion, but primary endpoints not met.

When this study was published

2026 study

The bigger picture

The near-significant ECV and significant LV mass reduction provide biological plausibility for CBD's cardiac anti-inflammatory effects.

Questions still open

  • Would a larger trial reach ECV significance? Would CBD help more in severe myocarditis? Could it prevent progression to cardiomyopathy?

Common questions

Did CBD help with myocarditis?
Primary markers did not significantly improve (p=0.054 for ECV). The significant LV mass reduction suggests some anti-inflammatory benefit worth further study.
Is this the first heart CBD trial?
Yes. The ARCHER study is the first RCT of pharmaceutical CBD in cardiac inflammation.

Read the original research

Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.

ESC heart failure, 13(1)

Citation

McNamara, Dennis M; Cooper, Leslie T; Friedrich, Matthias G; Arbel, Yaron; Bhimaraj, Arvind; Bocchi, Edimar; Hamer, Andrew; Herdy, Artur Haddad; Kerneis, Mathieu; Liu, Peter P; Parker, Andrea B; Pocock, Stuart J; Smith, Eldon R; Tang, W H Wilson; Torre-Amione, Guillermo; Tschöpe, Carsten. (2026). Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.. ESC heart failure, 13(1). https://doi.org/10.1093/eschf/xvaf034

Explore the wider topic